Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-751 plus docetaxel versus docetaxel alone in advanced or metastatic non-small cell lung cancer
2006-002838-38Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abt-751 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Progression-free survival and Maximum tolerated dose. Started Jan 2007; status: terminated.
02
Drugs
abt-751
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-002838-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002838-38.